TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Severe maternal morbidity (SMM)
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of depression symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in visual discomfort (SSQ score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of progressing to surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean leakage values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum serum concentrations of ezetimibe
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum serum concentrations of glucuronide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fecal excretion of ezetimibe
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: mean number of urge incontinence episodes per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PC35sGaw for LTD4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: decreased postsurgical morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: higher overall long-term patient satisfaction with genioplasty outcome
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Completion of screening
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Polyp number
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Apoptotic ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: analgesia in the foot
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increases in moderate-intensity PA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increases in vigorous-intensity PA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increases in total PA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implant and prostheses survival rates
Endpoint domain: Mortality/survival
Primary endpoint: Moderate/severe discomfort
Endpoint domain: Adverse events/effects
Primary endpoint: Severe discomfort
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of necrotic core
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plantar pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time spent on MVPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Moderate physical activity in leisure time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: speed of ambulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of CNV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perinatal mortality rates
Endpoint domain: Mortality/survival
Primary endpoint: Malignancies
Endpoint domain: Adverse events/effects
Primary endpoint: Median Tumor Shrinkage (TS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: implant failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: biomechanical complications
Endpoint domain: Adverse events/effects
Primary endpoint: Average RSO(2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Increase in extroversion
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Increase in emotional stability
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Frequency of nocturnal hypoglycaemia
Endpoint domain: Adverse events/effects
Primary endpoint: Withdrawal symptoms decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective reward/satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: fewer errors in visual attention/task switching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: better receptive language
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WOMAC pain subscore
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination of salivary MS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative FiO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of exposure to high FiO2 (>0.60)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: IGFBP7 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left atrial volume index (LAVi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Development of CLABSI
Endpoint domain: Adverse events/effects
Primary endpoint: Development of VTE
Endpoint domain: Adverse events/effects
Primary endpoint: Moderate bleeding requiring thrombogenic dressing
Endpoint domain: Adverse events/effects
Primary endpoint: Increased counts of intestinal Bifidobacterium, Lactobacillus, and Enterococcus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lowered counts of Escherichia coli and Staphylococcus aureus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Increased serum levels of IL‐2, IgA, IgG, IgM and CD4(+) cell percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mock injection time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dose accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intuitiveness rating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: arrest trends
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in CM volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bleaching Effect (BE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reaction times during optic flow conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Oral Health-Related Quality of Life (OHRQoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Antibody titres post-vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of patients achieving LDL-C goal of < 3.0 mmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PONV intensity score at 6 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PONV intensity score at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NRS Best Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NASS Outcome Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: incidence of at least moderate renal dysfunction (eGFR <60)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: laparoscopic skill acquisition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Admission with respiratory distress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Successful continuation of breast feeding
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Number of ultrasounds per 1000 mammograms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of breast cancers detected per 1000 mammograms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: incidence of postoperative side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of AK quantity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ki‐67 protein expression reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: p53 protein expression reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persisting anti-NY-ESO-1 immunity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Peri-implant marginal bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Patient satisfaction for function and aesthetics
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Completion of all needed services
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Completion of all needed vaccinations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Any vaccination
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cardiovascular risk associated with CRP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CD4+ cell counts in peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: humoral immune response suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: endocrine‐metabolic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: LTC(4) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: ECP concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Need for beta(2)-agonists
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Probing depth (PD) reductions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma-concentration time curve at steady state (AUCss,tau)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum steady-state concentration (Css,max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to reach Css,max (tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of deep venous thrombosis (DVT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: VEGF concentration in aqueous fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GHBP activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of different vegetables tried
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall task performance time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: workplace days lost
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: household work days lost
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: interference of arthritis on patient productivity
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: diet degree non‐adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: continuous ambulatory peritoneal dialysis (CAPD) non‐adherence degree
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: overall health and satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Response Rate (RR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Clinical Benefit Rate (CBR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: de novo endometrial polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Force production capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean voluntary activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete regression of spinal anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time for home discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global patient satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: mean percentage increase in papillary height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS assessments
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Bioavailability of enteral ciprofloxacin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of hypoglycemic events below 65 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: total improvement rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Temporal Sensory Summation (TSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time for T(1) to reach 25% of baseline value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time for TOF ratio to return to 0.7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of the DMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemoglobin level at testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Underweight prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement on the Davidson Trauma Scale (DTS) sleep item
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement on the Clinical Global Impressions‐Improvement scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of nausea, vomiting, fever and pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time of symptoms persistence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone marrow inhibition of chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Maximum Voluntary Contraction (%MVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Activation Duration (aDUR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Time to Activation (tACT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: septic morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: Achieved postoperative refraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of coronary events
Endpoint domain: Mortality/survival
Primary endpoint: Mean YMRS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Side effects leading to discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Objective measures of BOO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective measures of BOO
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time of hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Time until bony union
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage excess weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patients' treatment satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: incidence of residual disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of residual skin-tags
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall patient satisfaction index
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Median survival of myeloma patients
Endpoint domain: Mortality/survival
Primary endpoint: Serum RSV-neutralizing antibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum half-life of MEDI8897
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relapse behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of absorption of oxycodone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Role physical
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reliability of the Spanish PUF questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Adherence to VTE prophylaxis
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prostate-Specific Antigen (PSA) decline ≥ 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stenosis bothersomeness index
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceptions of signs and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arrhythmic endpoint (combined sudden death + ICD discharge)
Endpoint domain: Mortality/survival
Primary endpoint: Plasma vitamin C concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Markers of inflammation (total leukocyte counts, neutrophil counts and IL‐6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Volume of blood products transfusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: immune status indicators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: final weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Metacognitive strategies (ESESLS)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Self-concept (SCSC)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Preference rating for silicone prosthesis vs CPE
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: MR (molecular response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of ascites flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of EpCAM-positive malignant cells in ascites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Need for paracentesis
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Lower infection rates
Endpoint domain: Adverse events/effects
Primary endpoint: Complications after sinus surgeries
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum K
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive and memory improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Acceptance of photographic technique
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Repeatability of measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of rectal bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: suppression of acid output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement in attitudes towards mental illness
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Enhanced social integration of patients
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Reduction of abdominal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement of health‐related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Gait Fatigue Index (GFI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MOCA scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically significant phrenic nerve stimulation (PNS)
Endpoint domain: Adverse events/effects
Primary endpoint: Surgical LV lead revision rate
Endpoint domain: Adverse events/effects
Primary endpoint: Change in C-peptide secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean global gastrointestinal scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Solid-phase gastric emptying (GER)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Colonic transit (CTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: mean %ΔSμH after acid challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes